ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF)
Myelodysplastic Syndrome (MDS)
Gamida Cell ltdCell therapyPhase 3Dormant
BB
69/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 56/ 100
- Competitive Position
- 95/ 100
Competitive context
315 Active assets in the Myelodysplastic Syndrome (MDS) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 4 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
FILGRASTIM City of Hope Medical Center | Phase 4 | BB |
Fludarabine Sawa Ito, MD | Phase 4 | BB |
Daunorubicin OHSU Knight Cancer Institute | Phase 3 | BB |
View all 50 →
Same molecule, other indications
ALLOGENEIC, EX VIVO EXPANDED, UMBILICAL CORD BLOOD-DERIVED HEMATOPOIETIC CD133+ PROGENITOR CELLS- CULTURED FRACTION (CF) is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →